Log in to search using one of your social media accounts:

 

Trans-ungual Delivery of AR-12, a Novel Antifungal Drug.
AAPS PharmSciTech. 2017 Mar 13. doi: 10.1208/s12249-017-0752-y.Kushwaha AS, Sharma P, Shivakumar HN, Rappleye C, Zukiwski A, Proniuk S, Murthy SN.AR-12 is a novel small molecule with broad spectrum antifungal activity. Recently, AR-12 was found to be highly active against Trichophyton rubrum, one of the predominantly responsible organisms that cause onychomycosis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Efinaconazole 10% Topical Solution for Onychomycosis Efinaconazole 10% Topical Solution for Onychomycosis
This brief report summarizes the results of the latest Phase III trials on efinaconazole 10% nail solution, which shows potential as an antifungal therapy for the treatment of onychomycosis.Skin Therapy Letter (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 16, 2017 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Moberg obtains approvals to initiate Phase III trial of MOB-015 to treat onychomycosis
Swedish-based pharmaceutical company Moberg Pharma has obtained the US Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application, as well as a no-objection letter from Health Canada to start its Phase III trial of … (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2016 Category: Pharmaceuticals Source Type: news

Treating Onychomycosis With Laser Light
Title: Treating Onychomycosis With Laser LightCategory: Doctor's & Expert's views on SymptomsCreated: 6/7/2012 12:00:00 AMLast Editorial Review: 6/29/2016 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 29, 2016 Category: Dermatology Source Type: news

Is Testing Needed Before Treating Onychomycosis With Terbinafine?Is Testing Needed Before Treating Onychomycosis With Terbinafine?
Does it still make sense to order confirmatory testing prior to treating onychomycosis with oral terbinafine? Medscape Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2016 Category: Consumer Health News Tags: Dermatology Viewpoint Source Type: news

How the Care Team Concept Applies to the Management of Cutaneous Fungal Diseases (Medscape CME)
An interprofessional approach to treatment of patients with onychomycosis may be particularly valuable because of patient comorbidities and recurrent infection. Good communication between the different members of the team that includes the primary care physician, dermatologist, and nurse practitioner is essential. The activity presented here illustrates how the interprofessional approach can work in this setting. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 13, 2016 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Maximizing bang in topical onychomycosis therapy
WAIKOLOA, HAWAII – Two recent studies highlight several key points regarding topical therapy for onychomycosis: Treat it early for best results, and if concomitant tinea pedis is present, be sure to... (Source: Pediatric News)
Source: Pediatric News - March 9, 2016 Category: Journals (General) Source Type: news

VIDEO: Which patients are best for new onychomycosis topicals?
WAIKOLOA, HAWAII – Two new topical treatments for nail fungal infections are more effective than previous topical therapies, but the key to successful results is picking the right onychomycosis patient, according to Dr. Theodore Rosen. The two new agents, tavaborole and efinaconazole, “are both... (Source: Skin and Allergy News)
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news

VIDEO: Which patients are best for new onychomycosis topicals?
WAIKOLOA, HAWAII – Two new topical treatments for nail fungal infections are more effective than previous topical therapies, but the key to successful results is picking the right onychomycosis... (Source: Family Practice News)
Source: Family Practice News - February 17, 2016 Category: Primary Care Source Type: news

Tavaborole 5% Solution for Toenail OnychomycosisTavaborole 5% Solution for Toenail Onychomycosis
The first antifungal in a boron-containing class of drugs with a novel mechanism of action, tavaborole is able to penetrate the nail plate more effectively than other topical agents. Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 22, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Why Should We Care If Onychomycosis Is Truly Onychomycosis?Why Should We Care If Onychomycosis Is Truly Onychomycosis?
This commentary points out that while onychomycosis is generally not a disabling disease, in certain populations it may have implications for management of a more serious condition. The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 16, 2015 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Viamet begins Phase IIb trial of oral VT-1161 to treat onychomycosis
US-based Viamet Pharmaceuticals has started a Phase IIb clinical trial (RENOVATE) of VT-1161, a novel, orally-available, highly potent and selective inhibitor of fungal CYP51, to treat toenail onychomycosis. (Source: Drug Development Technology)
Source: Drug Development Technology - March 11, 2015 Category: Pharmaceuticals Source Type: news

Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report...
RnRMarketResearch.com adds “Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2015” report to its store. The report provides an overview of the onychomycosis’s therapeutic pipeline.(PRWeb February 13, 2015)Read the full story at http://www.prweb.com/releases/2015-onychomycosis-tinea/unguium-pipeline-review/prweb12517232.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2015 Category: Pharmaceuticals Source Type: news

Guidelines for the Management of Onychomycosis 2014Guidelines for the Management of Onychomycosis 2014
The guidelines presented in this article provide up-to-date, evidence-based recommendations for the diagnosis and management of fungal disease of the nails. The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2014 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Onychomycosis and Bronchiolitis Therapeutics Clinical Trial Review H2...
RnRMarketResearch.com adds “Onychomycosis and Bronchiolitis Global Clinical Trials Review H2 2014” to its store. The report provides elemental information and data relating to the clinical trials on...(PRWeb December 13, 2014)Read the full story at http://www.prweb.com/releases/bronchiolitis-onychomycos/clinical-trials-review-h2/prweb12392050.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 14, 2014 Category: Pharmaceuticals Source Type: news

Antifungal formulation improves penetration through nail plate
A new formulation of topical efinaconazole allows the antifungal to penetrate through the nail plate much better than do existing treatments for onychomycosis, according to a report in the December issue of Journal of Drugs in Dermatology. Poor nail penetration and diffusion through the thick,...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - December 11, 2014 Category: Dermatology Tags: FPN News FPN Cardiology IMN News IMN Cardiology SAN Journals SAN Clinical News SAN News Source Type: news

Topical efinaconazole permeates nail to infection
Topical efinaconazole’s ability to permeate the nail to the infection in onychomycosis is not hampered by the presence of infection or nail thickness, according to data from a multicenter, open-label study. Adult patients with onychomycosis treated with efinaconazole 10% solution for 4 weeks had...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 13, 2014 Category: Dermatology Tags: SAN Journals SAN Clinical News SAN News SAN Fungal FPN Journals FPN News FPN Dermatology Source Type: news

Moberg reports positive MOB-015 Phase II trial results in patients with onychomycosis
Moberg Pharma has reported successful top-line results from a Phase II trial of MOB-015 to treat patients with onychomycosis (nail fungus). (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2014 Category: Pharmaceuticals Source Type: news

Moberg Pharma announces successful results for MOB-015 in a Phase II study for the treatment of onychomycosis
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - September 17, 2014 Category: Pharmaceuticals Source Type: news

Dermatophytic Onychomycosis Therapeutics Market: Global Industry...
Transparency Market Research has added a new report titled "Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020"...(PRWeb August 23, 2014)Read the full story at http://www.prweb.com/releases/2014/08/prweb12114504.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 24, 2014 Category: Pharmaceuticals Source Type: news

FDA OKs Another Topical Drug for Onychomycosis (Kerydin) FDA OKs Another Topical Drug for Onychomycosis (Kerydin)
The drug is the first oxaborole antifungal for topically treating this infection in the toenail. The FDA approved another topical remedy just last month. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2014 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

FDA OKs First Topical Triazole Antifungal for OnychomycosisFDA OKs First Topical Triazole Antifungal for Onychomycosis
Efinaconazole (Jublia) is the first triazole antifungal to be developed for the treatment of distal lateral subungual onychomycosis. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2014 Category: Consumer Health News Tags: Dermatology News Source Type: news

Efinaconazole: A New Topical Treatment for OnychomycosisEfinaconazole: A New Topical Treatment for Onychomycosis
Efinaconazole solution shows promise in comparison to the currently available topical prescription and over-the-counter options for the treatment of subungual onychomycosis. Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2014 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

US Dermatophytic Onychomycosis Market Discussed by GlobalData in...
Topical research report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData has been recently published by Market Publishers Ltd.(PRWeb July 17, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10937702.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 18, 2013 Category: Pharmaceuticals Source Type: news

No FDA Okay Yet for Topical Onychomycosis Drug No FDA Okay Yet for Topical Onychomycosis Drug
The FDA has raised questions about manufacturing and controls related to the drug's container, but not efficacy or safety, in a complete response letter. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2013 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

Valeant says FDA denies approval to nail infection drug
(Reuters) - Canada drugmaker Valeant Pharmaceuticals International said on Tuesday that the U.S. Food and Drug Administration denied approval for its drug to treat onychomycosis, a fungal infection of the nail. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Anacor reports positive preliminary results from tavaborole Phase III onychomycosis trial
Biopharmaceutical company Anacor Pharmaceuticals has reported positive preliminary results from the first of two Phase III trials of topical anti-fungal tavaborole, designed to treat onychomycosis. (Source: Drug Development Technology)
Source: Drug Development Technology - January 31, 2013 Category: Pharmaceuticals Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at http://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news